State Street Corp Sells 22,700 Shares of Inari Medical, Inc. (NASDAQ:NARI)

State Street Corp cut its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 1.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,035,602 shares of the company’s stock after selling 22,700 shares during the period. State Street Corp owned about 3.48% of Inari Medical worth $83,948,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after acquiring an additional 435 shares in the last quarter. GAMMA Investing LLC lifted its stake in Inari Medical by 67.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock valued at $49,000 after acquiring an additional 473 shares in the last quarter. KBC Group NV lifted its stake in Inari Medical by 39.0% during the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after acquiring an additional 498 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Inari Medical during the 2nd quarter worth $104,000. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Stock Performance

Shares of NARI opened at $56.75 on Tuesday. The business has a 50-day moving average of $49.03 and a 200 day moving average of $47.99. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $67.10. The firm has a market cap of $3.32 billion, a P/E ratio of -42.04 and a beta of 0.97.

Analysts Set New Price Targets

NARI has been the topic of a number of recent analyst reports. Robert W. Baird lifted their target price on Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 29th. Leerink Partners initiated coverage on Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price on the stock. Truist Financial lifted their target price on Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research note on Tuesday, October 29th. Piper Sandler lifted their target price on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 29th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Inari Medical currently has a consensus rating of “Hold” and a consensus price target of $58.89.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 60,000 shares of Inari Medical stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the completion of the transaction, the director now owns 501,233 shares of the company’s stock, valued at $25,643,080.28. The trade was a 10.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at $22,265,500. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 143,000 shares of company stock valued at $7,022,400 in the last quarter. 10.60% of the stock is currently owned by corporate insiders.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.